Monday, May 12


TYSABRI: Low Body Weight Linked to PML Risk With Natalizumab in MS 

Genetic risk variants in African Americans with multiple sclerosis.

Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function: Treatment with dalfampridine resulted in clinically relevant improvements in walking speed and endurance in MS patients with limited ambulation and helped improve their motor function.

NEW MS TREATMENT: Plegridy (Biogen Idec) given every 2 weeks to patients with relapsing multiple sclerosis (MS) significantly reduced annualized relapse rates

New Data on How MS Patients Fare Long-Term: Patients with multiple sclerosis (MS) die about 6 years earlier than those in the general population; they don't get cancer as often and they don't seem to gain significant benefit from therapy in terms of disability progression.

Multiple Sclerosis: Autoimmune or Neurodegenerative?

NEW MS TREATMENT: More Phase 3 Data on Peginterferon in MS. One-year results suggest that peginterferon-β1a (Plegridy, Biogen Idec) has the potential to offer the efficacy and safety of currently available interferon agents for the treatment of relapsing multiple sclerosis (MS), with the added benefit of reduced frequency of administration

NARCOMS: 20 Years of MS Research

Tumefactive multiple sclerosis in taiwan.

Characterization of Microcirculation in Multiple Sclerosis Lesions by Dynamic Texture Parameter Analysis (Texture analysis is an alternative method to quantitatively assess MR-images

Detection of clinical relapses in multiple sclerosis cohorts: construction and validation of a model based on administrative data.

A Further TWEAK to Multiple Sclerosis Pathophysiology.

Utility of Disease-Specific Measures and Clinical Balance Tests in Prediction of Falls in Persons With Multiple Sclerosis.

Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair.

Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.

Cognition in Early Relapsing-Remitting Multiple Sclerosis: Consequences May Be Relative to Working Memory.

Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies

 Evaluation of an albumin-binding gadolinium contrast agent in multiple sclerosis.